JHK Medical Science Inc.
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Medical Devices
JHK Medical Science Inc. is a company specializing in the early detection of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI). Founded in 2020 by CEO Seo Yun Jo (MD, Ph.D.), the company is developing a high-precision, blood-based In Vitro Diagnostic (IVD) kit leveraging proprietary biomarkers. Its platform integrates proprietary IVD & recombinant antibodies & antigen design, and immunoassay technologies to enable clinically applicable diagnostics. By targeting the MCI stage, the company aims to address the limitations of current diagnostic methods, which are often invasive, costly, or inaccessible. The company is positioned to enter the global Alzheimer’s diagnostics market and is advancing clinical validation through U.S.-based cohort studies and collaborations with Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. It plans to leverage a Laboratory Developed Test (LDT) pathway for initial market entry while preparing for FDA regulatory approval.
Company HQ City:
Daejeon
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2020
Lead Product in Development:
5 types of in vitro diagnostic (IVD) & Recombinant Antibody
CEO
Seo Yun Jo
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Total: 9 unlicensed products are currently open for partnership opportunities
- 5 biomarker-based diagnostic kits
- 4 Software based technologies
Seeking strategic partnerships with U.S.-based CROs, human biospecimen banks, and Series A or later-stage investors
When you expect your next catalyst update?
October 2026 - December 2026
What is your next catalyst (value inflection) update?
Development of proprietary in vitro diagnostic (IVD) antibodies for five diagnostic biomarkers using a proprietary mode
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}